Literature DB >> 15921006

Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomized controlled trial. MRC asymptomatic carotid surgery trial (ACST) collaborative group. Lancet 2004; 363: 1491-502.

Naufal Mohammed1, Sonia S Anand.   

Abstract

QUESTION: Is carotid endarterectomy (CEA) an effective and safe treatment for the prevention of stroke among patients with >60% internal carotid artery stenosis who had no neurologic symptoms in the previous 6 months. POPULATION: Men and women with severe (>60%) unilateral or bilateral carotid artery stenosis not associated with neurologic symptoms in the past 6 months, where both doctor and patient were uncertain whether to choose or to defer immediate CEA. DESIGN AND METHODS: During 1993-2003, 3120 asymptomatic patients with >60% carotid stenosis were randomized equally to immediate CEA versus indefinite deferral of CEA, and were followed for up to 5 years. The primary end point was risk of stroke or death at 5 years. Analysis was by intention to treat. The treatment of patients with antiplatelet agents, antihypertensive and lipid-lowering therapies was left to the discretion of the clinician.
RESULTS: Among patients randomized to immediate CEA (50% had CEA by 1 month, 88% by 1 year) versus deferred, the incidence of stroke or death at 5 years was 6.4% versus 11.8% (95% CI: 3.0-7.7, p < 0.0001); 3.5% versus 6.1% for fatal or disabling strokes (95% CI: 0.8-4.3, p = 0.004), and 2.1% versus 4.2% for fatal strokes (95% CI: 0.6-3.6, p = 0.006). The perioperative stroke incidence was marginally higher in the delayed group versus the immediate group (4.5% versus 2.8%) and overall the risk per CEA of perioperative stroke or death was 3.1%. After excluding the perioperative events from the analysis, the 5-year stroke risks were 3.8% versus 11% (95% CI: 5.0-9.4], p < 0.0001). Surgery primarily prevented carotid territory ischemic strokes (2.7% vs 9.5%; gain 6.8% [4.8-8.8], p < 0.0001). The impact of immediate surgery was consistent in all age groups, among men and women, and across the spectrum of carotid stenosis (i.e. 70%, 80% and 90% carotid stenosis).
CONCLUSION: In asymptomatic patients younger than 75 years of age with carotid stenosis of 70% or more on ultrasound, immediate CEA reduces the 5-year incidence of stroke and death.

Entities:  

Year:  2005        PMID: 15921006     DOI: 10.1191/1358863x05vm588xx

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  6 in total

Review 1.  Stroke Risk Factors, Genetics, and Prevention.

Authors:  Amelia K Boehme; Charles Esenwa; Mitchell S V Elkind
Journal:  Circ Res       Date:  2017-02-03       Impact factor: 17.367

Review 2.  Carotid revascularization: risks and benefits.

Authors:  Marlene O'Brien; Ankur Chandra
Journal:  Vasc Health Risk Manag       Date:  2014-07-07

Review 3.  Carotid Artery Stenting.

Authors:  Jae Hyeong Park; Jae Hwan Lee
Journal:  Korean Circ J       Date:  2017-11-15       Impact factor: 3.243

4.  The Nature of Iron Deposits Differs between Symptomatic and Asymptomatic Carotid Atherosclerotic Plaques.

Authors:  David Kopriva; Anastasye Kisheev; Deiter Meena; Shaneen Pelle; Max Karnitsky; Andrea Lavoie; Josef Buttigieg
Journal:  PLoS One       Date:  2015-11-25       Impact factor: 3.240

5.  One-year experience in carotid endarterectomy combining general anaesthesia with preserved consciousness and sequential carotid cross-clamping.

Authors:  Alessandro Ucci; Rita Maria D'Ospina; Mara Fanelli; Giulia Rossi; Federica Persi; Franca Bridelli; Michela Tosi; Claudio Bianchini Massoni; Paolo Perini; Bilal Nabulsi; Alessandro De Troia; Tiziano Tecchio; Matteo Azzarone; Antonio Freyrie
Journal:  Acta Biomed       Date:  2018-03-27

6.  Correlation Between Calcification Characteristics of Carotid Atherosclerotic Plaque and Plaque Vulnerability.

Authors:  Xiangli Xu; Yang Hua; Beibei Liu; Fubo Zhou; Lili Wang; Weihong Hou
Journal:  Ther Clin Risk Manag       Date:  2021-07-01       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.